📈🚀 NNVC Advances Pipeline in Expanding Global Biotech Market

👀 Investor Watch: NV-387 enters human trials—first-in-class therapy targeting multi-billion cancer virus markets.  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­

Unsubscribe A message from Interactive Offers NanoViricides, Inc. (NYSE American: NNVC) Advances Dual-Action Therapy in $200B Oncology & Antiviral Industries The company's lead drug, NV-387, is advancing into Phase II clinical trials — with the potential to transform both cancer care and antiviral treatment. Here's why this matters to investors: Cancer Recurrence Prevention: Viral infections like COVID-19, Influenza, RSV, and measles can "wake up" dormant cancer cells, fueling deadly metastasis. NV-387's unique antiviral and anti-inflammatory properties—including reduced IL-6 cytokine levels—may stop this process before it starts. Best-in-Class Data: Preclinical studies show NV-387 provides superior lung protection and dramatically lowers inflammation versus leading antivirals (Tamiflu, Rapivab, Xofluza). Massive Market Potential: By addressing viral infections and cancer recurrence prevention, NV-387 could unlock multi-billion-dollar opportunities across oncology and infectious disease markets. Platform Advantage: NanoViricides' exclusive nanoviricide™ technology is designed to block viral escape—even against new and evolving variants. With COVID-19 now endemic, seasonal influenza surging, and cancer recurrence remaining one of medicine's greatest challenges, NV-387 is positioned at the crossroads of oncology and virology. This is more than a clinical milestone—it could be a medical revolution. As NNVC moves deeper into human trials, investors now have the chance to get in front of what may become a first-in-class therapy protecting millions of patients worldwide. 👉 [Learn More About NNVC and NV-387's Breakthrough Potential] This message is a PAID ADVERTISEMENT for NanoViricides, Inc (NYSE: NNVC) from Interactive Offers. StockEarnings, Inc. has received a fixed fee of $7000 from Interactive Offers for multiple Dedicated Email Sends, Newsletter Sponsorships and SMS Sends between September 2, 2025 and September 5, 2025. Other than the compensation received for this advertisement sent to subscribers, StockEarnings and its principals are not affiliated with either NanoViricides, Inc (NYSE: NNVC) or Interactive Offers. StockEarnings and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither StockEarnings nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from StockEarnings to buy or sell any security. StockEarnings has not evaluated the accuracy of any claims made in this advertisement. StockEarnings recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding NanoViricides, Inc (NYSE: NNVC) on Smallcaps Daily website for additional information about the relationship between Interactive Offers and NanoViricides, Inc (NYSE: NNVC). Your privacy is very important to us, if you wish to be excluded from future notices, do not reply to this message. Instead, please click Unsubscribe. StockEarnings, Inc 33 SE 4th St, Suite 100, Boca Raton, FL 33432 USA W: 877.6.STOCKS StockEarnings.com